About Dermata Therapeutics
Dermata Therapeutics is a company based in San Diego (United States) founded in 2014 by Gerry Proehl. Dermata Therapeutics has raised $15.67 million across 11 funding rounds from investors including SVB and H.C. Wainwright & Co. The company has 8 employees. Dermata Therapeutics offers products and services including DMT410. Dermata Therapeutics operates in a competitive market with competitors including Revance Therapeutics, Dermavant, Sol-Gel Technologies, SkinMedica and Hugel, among others.
- Headquarter San Diego, United States
- Employees 8
- Founders Gerry Proehl
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website dermatarx.com
- Social LinkedIn
- Legal Name Dermata Therapeutics, Inc.
- Net Profit-$7.56 M (USD)38.49as on Dec 31, 2025
- EBITDA-$7.77 M (USD)37.88as on Dec 31, 2025
- Total Equity Funding$15.67M (USD)
in 11 rounds
- Latest Funding Round$4.12M (USD), Post-IPO
Dec 2025
- InvestorsSVB
& 1 more
- Employee Count8
Products & Services of Dermata Therapeutics
Dermata Therapeutics offers a comprehensive portfolio of products and services, including DMT410.
Innovative therapy for skin diseases like acne and psoriasis.
Funding Insights of Dermata Therapeutics
Dermata Therapeutics has successfully raised a total of $15.67M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4.12 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.67M
- Total Rounds 11
- Last Round Post-IPO — $4.12M
- First Round $608,050
(Feb 2015)
- Investors Count 2
Latest 10 of 11 funding rounds of Dermata Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2025 | $4.12M | Post-IPO | – | – | – |
| Jan 2025 | $2.55M | Post-IPO | – | – | – |
| Sep 2024 | $3.5M | Post-IPO | – | – | |
| May 2023 | – | Post-IPO | – | – | – |
| Dec 2020 | $3M | Debt – Conventional | – | – | – |
| Feb 2017 | $2.5M | Series A | – | – | – |
| Feb 2017 | $5M | Debt – Venture | – | – | |
| Nov 2016 | $5M | Series A | – | – | – |
| Jan 2016 | $6.91M | Series A | – | – | – |
| Jun 2015 | $651,305 | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Dermata Therapeutics
Dermata Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include SVB and H.C. Wainwright & Co.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
H.C. Wainwright & Co. is engaged in investment banking and advisory services. | – | hcwco.com | New York, United States | |
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States |
Investor details for Dermata Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Dermata Therapeutics
11 people are tracked at Dermata Therapeutics (4 in leadership, 6 in board & advisors, 1 in team); the tracked headcount is 8.
| Name | Role | Group |
|---|---|---|
Gerry Proehl | Founder & CEO | Leadership |
Trevor Rader | Sr. Director, Pharmaceutical Technology | Leadership |
Kyri Van Hoose | SVP, CFO | Leadership |
Chris Nardo | SVP & Chief Development Officer | Leadership |
David Hale | Director | Board & advisors |
Wendell Wierenga | Director | Board & advisors |
Mary Fisher | Director | Board & advisors |
Steve Mento | Director | Board & advisors |
Andrew Sandler | Director | Board & advisors |
Kathleen Scott | Director | Board & advisors |
Maria Bedoya Toro Munera | SVP, Regulatory Affairs & Quality Assurance | Team |
Complete people profiles for Dermata Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Dermata Therapeutics
Dermata Therapeutics is a publicly listed company on the NASDAQ with ticker symbol DRMA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 Aug 2021
- Listed onNASDAQ: DRMA
- Listed entityDermata Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS2498455045
- Share price$1.02 (-4.67% on the day) · 2026-10-09
- Market capitalisation$4.1M
- EPS (diluted, trailing year)$-4.39
- Volume (last session)22,518
Financials of Dermata Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$7.6M | -$7.8M |
| 2024 | – | -$12.3M | -$12.5M |
| 2023 | – | -$7.8M | -$8.0M |
| 2022 | – | -$9.6M | -$9.7M |
| 2021 | – | -$7.9M | -$7.9M |
Detailed financial statements for Dermata Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Dermata Therapeutics
4 dated milestones of Dermata Therapeutics across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Dermata Therapeutics is founded.
- Funding First funding round of $608K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $4.1M.
Competitors of Dermata Therapeutics
Dermata Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Dermavant, Sol-Gel Technologies, SkinMedica and Hugel, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| dermavant.com | 2016 | Phoenix, United States | $160M | – | Small molecule therapeutics for inflammatory skin diseases are developed. | |
| sol-gel.com | 1998 | United States | $9M | – | Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. | |
| skinmedica.com | 1999 | Carlsbad, United States | $94.24M | – | Skin care products are developed and manufactured by SkinMedica. | |
| hugel.co.kr | 2001 | Chuncheon-si, South Korea | – | – | Therapeutics in aesthetics are developed, including botulinum toxin products. | |
| collplant.com | 2004 | Ness Ziona, Israel | $16.3M | – | Plant-derived collagen is developed for tissue repair and 3D bioprinting. | |
| biofrontera.com | 1997 | Leverkusen, Germany | – | 149 | Solutions for dermatological therapeutics and consumer products are provided. | |
| sofregen.com | 2014 | Medford, United States | $17.8M | 8 | Silk-derived biomaterials are developed for soft tissue repair in surgery. | |
| histogen.com | 2007 | San Diego, United States | $51.4M | 22 | Regenerative medicine is developed using embryonic cell alternatives. |
Detailed competitors of Dermata Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dermata Therapeutics
The website of Dermata Therapeutics (dermatarx.com) receives about 3.5K visits a month.
- Monthly visits3.5K
▲ 22.6% vs previous month
Latest news on Dermata Therapeutics
Complete news archive for Dermata Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Dermata Therapeutics
10 companies that operate in the same segment as Dermata Therapeutics (Dermatology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Developer of drugs for treating dermatology diseases | 1908 | Copenhagen, Denmark | USD 560.38 M | – | – | |
Skincare, beauty, and wellness services provided by VLCC across multiple countries. | 1989 | Delhi, Delhi, India | – | – | – | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608 M | – | – | |
Immunotherapeutic solutions for dermatological conditions are developed. | 2016 | Westlake Village, California, United States | USD 94.5 M | USD 376.07 M | 342 | |
Targeted small molecules are developed for oncology treatments. | 2010 | Singapore, Singapore | USD 100 M | – | – | |
Pharmaceutical formulations for dermatology, gastroenterology, and wellness are manufactured. | 2014 | Pune, Maharashtra, India | USD 25.97 M | USD 18.15 M | 508 | |
Novel dermatologic therapies are developed for skin conditions. | 2012 | Malvern, Pennsylvania, United States | USD 82 M | USD 7.83 M | 64 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Dermata Therapeutics
Dermata Therapeutics was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Dermata Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Gerry Proehl is the current CEO of Dermata Therapeutics. They have also founded this company.
Dermata Therapeutics is a funded company, having raised a total of $15.67M across 11 funding rounds to date. The company's 1st funding round was a Seed of $651.31K, raised on Feb 2015.
Dermata Therapeutics has 8 employees.
Dermata Therapeutics was established in 2014 in San Diego, United States, within the biotechnology sector. Focus is placed on developing treatments for dermatologic and ophthalmologic conditions. Operations center on innovative topical therapies, including XYNGARI, derived from freshwater sponge extract for moderate-to-severe acne and potential use in psoriasis and rosacea. Additionally, DMT410 serves as an intradermal delivery system to facilitate botulinum toxin penetration through microchannels for skin-related aesthetic and medical applications.
Dermata Therapeutics's top competitors include Revance Therapeutics, Dermavant and Collplant.
Dermata Therapeutics offers DMT410.
Yes, Dermata Therapeutics is publicly traded on NASDAQ under the ticker symbol DRMA.
Dermata Therapeutics has 2 investors. Key investors include SVB, and H.C. Wainwright & Co.
Dermata Therapeutics operates through Dermata Therapeutics, Inc..